KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Equity Income (2016 - 2019)

Historic Equity Income for CRISPR Therapeutics AG (CRSP) over the last 4 years, with Q3 2019 value amounting to -$3.4 million.

  • CRISPR Therapeutics AG's Equity Income fell 23893.28% to -$3.4 million in Q3 2019 from the same period last year, while for Dec 2019 it was -$5.5 million, marking a year-over-year decrease of 2788.3%. This contributed to the annual value of -$5.5 million for FY2019, which is 2788.3% down from last year.
  • As of Q3 2019, CRISPR Therapeutics AG's Equity Income stood at -$3.4 million, which was down 23893.28% from -$1.0 million recorded in Q2 2019.
  • In the past 5 years, CRISPR Therapeutics AG's Equity Income ranged from a high of -$359000.0 in Q3 2017 and a low of -$35.8 million during Q4 2016
  • Moreover, its 4-year median value for Equity Income was -$1.0 million (2018), whereas its average is -$3.7 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Equity Income skyrocketed by 9873.63% in 2017, and later plummeted by 23893.28% in 2019.
  • CRISPR Therapeutics AG's Equity Income (Quarter) stood at -$35.8 million in 2016, then skyrocketed by 98.74% to -$453000.0 in 2017, then tumbled by 124.94% to -$1.0 million in 2018, then plummeted by 236.6% to -$3.4 million in 2019.
  • Its Equity Income stands at -$3.4 million for Q3 2019, versus -$1.0 million for Q2 2019 and -$1.0 million for Q1 2019.